Almirall, Uxbridge, won a GBP 12.4 million (excluding VAT) multiple awardees contract award from the Common Services Agency (the Authority) for the supply of a range of analgesic, anaesthetic, musculoskeletal and joint disease medicines (All other Analgesic, Anaesthetic Musculoskeletal and Joint Disease Medicines) (Contract Award Notice No.: 2016/S 005-005020; Lot No.: 7).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.405 EUR | -1.21% |
|
-4.37% | +11.63% |
06-10 | Almirall: extension of indication in actinic keratosis | CF |
06-10 | Almirall’s Skin Disease Drug Gets US FDA Nod for Larger Treatment Area | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.63% | 2.13B | |
+55.95% | 811B | |
+43.62% | 640B | |
-6.98% | 353B | |
+19.08% | 333B | |
+9.05% | 302B | |
+16.30% | 246B | |
+2.41% | 225B | |
+12.47% | 218B | |
+8.91% | 168B |
- Stock Market
- Equities
- ALM Stock
- News Almirall, S.A.
- Almirall Wins GBP 12.4 Million Multiple Awardees Contract for Supplying Analgesic, Anaesthetic, Musculoskeletal and Joint Disease Medicines